|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC35B2 |
Gene summary for SLC35B2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC35B2 | Gene ID | 347734 |
| Gene name | solute carrier family 35 member B2 | |
| Gene Alias | PAPST1 | |
| Cytomap | 6p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q8TB61 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 347734 | SLC35B2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.02e-03 | 1.66e-01 | 0.0155 |
| 347734 | SLC35B2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.65e-03 | 2.19e-01 | -0.1808 |
| 347734 | SLC35B2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.75e-09 | 3.58e-01 | -0.0811 |
| 347734 | SLC35B2 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.86e-06 | 2.99e-01 | -0.1088 |
| 347734 | SLC35B2 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.90e-04 | 1.92e-01 | -0.1954 |
| 347734 | SLC35B2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.06e-09 | 2.41e-01 | -0.1464 |
| 347734 | SLC35B2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.81e-05 | 2.55e-01 | -0.059 |
| 347734 | SLC35B2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.22e-06 | 2.64e-01 | 0.096 |
| 347734 | SLC35B2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 9.21e-03 | 4.02e-01 | 0.0446 |
| 347734 | SLC35B2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.24e-04 | 2.26e-01 | 0.0338 |
| 347734 | SLC35B2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.62e-08 | 2.55e-01 | 0.0674 |
| 347734 | SLC35B2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.95e-14 | 2.80e-01 | 0.294 |
| 347734 | SLC35B2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.18e-05 | 5.23e-01 | 0.3487 |
| 347734 | SLC35B2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.37e-11 | 4.52e-01 | 0.281 |
| 347734 | SLC35B2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.98e-11 | 2.98e-01 | 0.3859 |
| 347734 | SLC35B2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.55e-05 | 3.09e-01 | 0.2585 |
| 347734 | SLC35B2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.62e-11 | 2.54e-01 | 0.3005 |
| 347734 | SLC35B2 | LZE2T | Human | Esophagus | ESCC | 4.54e-02 | 6.62e-01 | 0.082 |
| 347734 | SLC35B2 | LZE4T | Human | Esophagus | ESCC | 2.98e-04 | 1.46e-01 | 0.0811 |
| 347734 | SLC35B2 | LZE7T | Human | Esophagus | ESCC | 4.85e-05 | 4.91e-01 | 0.0667 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0009152 | Colorectum | AD | purine ribonucleotide biosynthetic process | 64/3918 | 169/18723 | 3.09e-07 | 1.22e-05 | 64 |
| GO:0009260 | Colorectum | AD | ribonucleotide biosynthetic process | 66/3918 | 182/18723 | 1.25e-06 | 4.02e-05 | 66 |
| GO:0046390 | Colorectum | AD | ribose phosphate biosynthetic process | 67/3918 | 190/18723 | 3.21e-06 | 9.05e-05 | 67 |
| GO:0006164 | Colorectum | AD | purine nucleotide biosynthetic process | 66/3918 | 191/18723 | 8.22e-06 | 1.97e-04 | 66 |
| GO:0072522 | Colorectum | AD | purine-containing compound biosynthetic process | 68/3918 | 200/18723 | 1.12e-05 | 2.55e-04 | 68 |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:1901293 | Colorectum | AD | nucleoside phosphate biosynthetic process | 80/3918 | 256/18723 | 6.31e-05 | 1.05e-03 | 80 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0009165 | Colorectum | AD | nucleotide biosynthetic process | 79/3918 | 254/18723 | 8.33e-05 | 1.30e-03 | 79 |
| GO:0043123 | Colorectum | AD | positive regulation of I-kappaB kinase/NF-kappaB signaling | 60/3918 | 186/18723 | 1.91e-04 | 2.56e-03 | 60 |
| GO:0043122 | Colorectum | AD | regulation of I-kappaB kinase/NF-kappaB signaling | 76/3918 | 249/18723 | 2.17e-04 | 2.85e-03 | 76 |
| GO:0007249 | Colorectum | AD | I-kappaB kinase/NF-kappaB signaling | 82/3918 | 281/18723 | 6.09e-04 | 6.40e-03 | 82 |
| GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC35B2 | SNV | Missense_Mutation | rs762279662 | c.1232C>T | p.Ala411Val | p.A411V | Q8TB61 | protein_coding | tolerated(0.11) | probably_damaging(0.999) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SLC35B2 | SNV | Missense_Mutation | c.707N>C | p.Glu236Ala | p.E236A | Q8TB61 | protein_coding | deleterious(0.01) | possibly_damaging(0.837) | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SLC35B2 | SNV | Missense_Mutation | rs752687684 | c.241N>A | p.Val81Met | p.V81M | Q8TB61 | protein_coding | deleterious(0.01) | possibly_damaging(0.887) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC35B2 | SNV | Missense_Mutation | c.263C>A | p.Ala88Asp | p.A88D | Q8TB61 | protein_coding | tolerated(0.47) | benign(0.005) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | |
| SLC35B2 | SNV | Missense_Mutation | c.474G>A | p.Met158Ile | p.M158I | Q8TB61 | protein_coding | tolerated(0.3) | benign(0.115) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SLC35B2 | SNV | Missense_Mutation | rs772679565 | c.290G>A | p.Arg97Gln | p.R97Q | Q8TB61 | protein_coding | tolerated(0.27) | benign(0.034) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| SLC35B2 | insertion | Frame_Shift_Ins | novel | c.754_755insGATA | p.Met252ArgfsTer32 | p.M252Rfs*32 | Q8TB61 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
| SLC35B2 | insertion | In_Frame_Ins | novel | c.752_753insGATGCCCTGTTTGCCTATAAGATGTCATCGGTG | p.Ser251delinsArgMetProCysLeuProIleArgCysHisArgCys | p.S251delinsRMPCLPIRCHRC | Q8TB61 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
| SLC35B2 | deletion | Frame_Shift_Del | novel | c.999delN | p.His334ThrfsTer38 | p.H334Tfs*38 | Q8TB61 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SLC35B2 | SNV | Missense_Mutation | rs138499828 | c.1252N>T | p.Arg418Trp | p.R418W | Q8TB61 | protein_coding | deleterious(0.03) | possibly_damaging(0.803) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |